Dr. Leighl continued her presentation on "Highlights in Lung Cancer, 2012" with a discussion of the challenges that many patients with squamous NSCLC face, typically not having a cancer with a "driver mutation" like an EGFR mutation or an ALK rearrangement.

Dr. Karen Reckamp, City of Hope Cancer Center, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

[powerpress]

Dr. Lecia Sequist provides her thoughts on how molecular oncology can soon begin affecting treatment plans for a broader range of patients with lung cancer, including those with squamous NSCLC and other lung cancer histologies.

[powerpress]

Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.

[powerpress]

Drs. Ross Camidge and Corey Langer discuss which patients with advanced NSCLC they would recommend should have a repeat biopsy if their initial tissue sample doesn't have sufficient tissue for molecular testing.

[powerpress]

The last topic covered by Dr. Neal was on exciting work on molecular targets for squamous NSCLC.